Genzyme: Engineering the Market for Orphan DrugsHenry W. Chesbrough, Clarissa CerutiDescrription: Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. More information: http://cb.hbsp.harvard.edu/cb/web/product_detail.seam?R=602147-PDF-ENG&conversationId=249439&E=36692 learning objective: Illustrates novel approach to targeting drug markets and creative ways to use external technology. |